The vasorelaxant effect of dipyrone on an experimental cerebral vasospasm model in rabbits

Abstract Cerebral vasospasm is an important clinical phenomenon associated with a high mortality rate and therefore any promising findings in the laboratory deserve assessment in clinical practice. Dipyrone (Metamizol) has been in clinical use for its non-narcotic analgesic effect since 1922. In addition to its analgesic effect, dipyrone has been shown to possess spasmolitic activity in various smooth muscle organs. In our recent study, it was shown that dipyrone also has a relaxing effect in vascular smooth muscle preparations and that the smooth muscle relaxing effect on the rabbit thoracic aorta was produced by one of dipyrone’s spontaneous degradation products. The present study was designed to examine the possible effects of dipyrone on the rabbit basilar artery in a model of cerebral vasospasm. Dipyrone was shown to have a clear spasmolitic effect in the rabbit basilar artery vasospasm produced by an intracisternal injection of autologous blood. This effect was apparent with either local or intravenous administration of dipyrone. These data suggest that dipyrone is potentially useful in the treatment of patients suffering from cerebral vasospasm in combination with other agents or alone. [Neurol Res 2000; 22: 815-818]

[1]  F. Tulunay,et al.  Pharmacological characterization of metamizol-induced relaxation in phenylephrine-precontracted rabbit thoracic aorta smooth muscle. , 1999, General pharmacology.

[2]  A. Valavanis,et al.  Improvement of cerebral oxygenation patterns and metabolic validation of superselective intraarterial infusion of papaverine for the treatment of cerebral vasospasm. , 1998, Journal of neurosurgery.

[3]  Z. Katušić,et al.  The effect of subarachnoid hemorrhage on mechanisms of vasodilation mediated by cyclic adenosine monophosphate. , 1998, Journal of neurosurgery.

[4]  N. Kassell,et al.  Intra-arterially administered papaverine for the treatment of symptomatic cerebral vasospasm. , 1998, Neurosurgery.

[5]  J. Wanebo,et al.  Enhanced endogenous antioxidant activity and inhibition of cerebral vasospasm in rabbits by pretreatment with a nontoxic endotoxin analog, monophosphoryl lipid A. , 1998, Journal of neurosurgery.

[6]  L. Sekhar,et al.  The efficacy and safety of angioplasty for cerebral vasospasm after subarachnoid hemorrhage. , 1998, Neurosurgery.

[7]  Y. Hirashima,et al.  Anticardiolipin antibody aggravates cerebral vasospasm after subarachnoid hemorrhage in rabbits. , 1998, Stroke.

[8]  V. Feigin,et al.  Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage , 1998, Neurology.

[9]  S. Howng,et al.  Systemic administration of the potassium channel activator cromakalim attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. , 1998, Neurosurgery.

[10]  J. P. Elliott,et al.  Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. , 1997, Journal of neurosurgery.

[11]  K. Takakura,et al.  Prophylactic effect of papaverine prolonged-release pellets on cerebral vasospasm in dogs. , 1998, Neurosurgery.

[12]  T. Pilgram,et al.  Increase in diameters of vasospastic intracranial arteries by intraarterial papaverine administration. , 1998, Journal of neurosurgery.

[13]  A. Fergus,et al.  Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. , 1997, Neurosurgery.

[14]  E. Oldfield,et al.  Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. , 1997, Journal of neurosurgery.

[15]  A. Jeng,et al.  Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. , 1997, Journal of neurosurgery.

[16]  J. B. Salom,et al.  Impairment of the modulatory role of nitric oxide on the endothelin-1-elicited contraction of cerebral arteries: a pathogenetic factor in cerebral vasospasm after subarachnoid hemorrhage? , 1997, Neurosurgery.

[17]  B. Vollrath,et al.  In vivo angioplasty prevents the development of vasospasm in canine carotid arteries. Pharmacological and morphological analyses. , 1997, Stroke.

[18]  G L Kongable,et al.  Innovations in Aneurysmal Subarachnoid Hemorrhage: Intracisternal t‐PA for the Prevention of Vasospasm , 1996, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[19]  M. Zuccarello,et al.  Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. , 1996, Journal of neurosurgery.

[20]  M. Başkaya,et al.  Protection by Iloprost (stable analogue of prostacyclin) of endothelial damage due to chronic vasospasm in dogs: an electron microscope study. , 1995, Neurological research.

[21]  B. Rosenkranz,et al.  Clinical Pharmacokinetics of Dipyrone and its Metabolites , 1995, Clinical pharmacokinetics.

[22]  M. Zuccarello,et al.  Endothelin ETA and ETB receptors in subarachnoid hemorrhage-induced cerebral vasospasm. , 1994, European journal of pharmacology.

[23]  K. Brune,et al.  Observer-blind study with metamizole versus tramadol and butylscopolamine in acute biliary colic pain. , 1993, Arzneimittel-Forschung.

[24]  J. Torner,et al.  A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. , 1993, Journal of neurosurgery.

[25]  M. Başkaya,et al.  The effect of Iloprost on chronic cerebral vasospasm. , 1993, General pharmacology.

[26]  M. Clozel,et al.  BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. , 1993, Life sciences.

[27]  D. Kaufman,et al.  AIDS Summary 91: A Practical Synopsis of the VII International Conference , 1992, Annals of Internal Medicine.

[28]  G. Murray,et al.  Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. , 1989, BMJ.

[29]  J. Öhman,et al.  Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. , 1988, Journal of neurosurgery.

[30]  D. Lowe,et al.  Early intervention with nimodipine in subarachnoid haemorrhage. , 1987, European heart journal.

[31]  T. J. Iberti.  Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. , 1983, Neurosurgery.